Worth mentioning …

November 2nd, 2006 by Kaitlin Thaney

In a recent interview on Bio-IT World, David de Graaf, first director of systems biology for Pfizer, gave a shout-out to us here at Science Commons, including us in the list of folks Pfizer is currently working with to explore ways to circumvent roadblocks to their systems biology work.

Speaking to John Russell, editor of Bio-IT World and SBNL, de Graaf said:

“Everybody keeps running into the same toxicity and we can’t solve it. Actually putting our heads together and, more importantly, putting our data together may be something that’s worthwhile, and we’re exploring that together with the folks at Science Commons right now, as well as the folks at

Outside of working with Teranode and the Science Commons team, de Graaf told Russell he is also working with the head of computational systems biology at Novartis, the director of pathways capability at AstraZeneca, as well as other contacts at Biogen Idec and Numerica Technologies.

Earlier in the interview, de Graaf spoke about current models generated at Pfizer’s Research Technology Center (RTC) both internally, and also with the help of Teranode. His comment about this collaboration is promising.

“One of the interesting things that happened with Teranode is we’re starting to see aspects of knowledge management around these larger systems biology projects, and together with Teranode, we’re pushing the envelope there in terms of what we can do. So we’re thinking about common shared spaces for data that can be accessed within Pfizer or by partners external to Pfizer, or even by competitors, with appropriate restrictions.”

To read the entire interview, click here .

2 Responses

  1. Biological content: Access and monetization at business|bytes|genes|molecules, on November 2nd, 2006 at 6:59 pm

    […] Update:I had totally forgotten about science commons, but thanks to a new post in my feed reader, I would like to point people there. The latest post is about an interview with David de Graaf, director of systems biology at Pfizer. I would like to point out that Teranode (where Eric works) is involved with science commons as well. […]

  2. Andre, on November 7th, 2006 at 2:40 am

    Knowledge Management is a big topic these days. There is a lot of knowledge unused in many firms – it is important to use this knowledge in the future. Science Commons is a way to deal with that problem.